A massive multi-center study reveals that the new 2026 AHA/ACC pulmonary embolism framework adds clinical complexity without improving risk prediction for the vast majority of patients.
Hospital administrators are treating clinical artificial intelligence as a cost-saving cure, but the frontline workforce sees a direct threat to patient safety.
The FDA is letting drugmakers recycle data from past trials to speed up gene therapies, but this regulatory shortcut places a massive burden of proof on developers.
An attention-based AI model has mapped the genetic boundaries between neurological and psychiatric diseases using nothing but raw electronic health records.